TPS250 Background: Fluoropyrimidine (FP) is a common chemotherapy class used across multiple tumor streams, including first line colorectal cancer management. Approximately 30% of patients develop serious toxicities with standard doses, potentially requiring hospitalization, intensive care admission and occasionally death. FP chemotherapy is primarily metabolized by dihydropyrimidine dehydrogenase (DPD, encoded by DPYD ), with DPD deficiency accounting for a significant number of serious toxicities. DPYD genotyping is a valid method of indirect measurement of DPD activity and has been implemented into routine care in some regions, enabling genotype-guided dosing. Despite mounting evidence, uptake of DPYD testing in Australia is currently sporadic and typically self-funded by the patient. This study will be the first to provide nation-wide prospective data on the feasibility and effectiveness of DPYD genotyping to direct FP dosing within the Australian health care system. Methods: This is a prospective, single arm, non-randomized study, aiming to recruit 5000 adult patients across Australia with solid organ malignancies intended to receive FP-based chemotherapy for the first time (trial registered 12/13/2023, Australian and New Zealand Cancer Trials Registry ACTRN12623001301651). DPYD genotyping will be performed for the key variants; c.1905+1G>A, ( DPYD *2A, rs3918290), c.2846A>T (rs67376798), c.1679T>G (DPYD*13, rs55886062.1) and c.1236G>A (rs56038477), with dose adjustments performed in accordance with published Australian guidelines. The primary outcome is incidence of serious (CTCAE v5.0 Grade 3+) FP-associated toxicities in the first 60 days in heterozygote DPYD variant carriers who receive a genotype-guided dose-adjustment, compared to: i) current standard of care (as assessed by a retrospective review of 500 consecutive cases); ii) contemporaneous cases without these variants treated with standard doses; and iii) variant carriers in this study that do not receive genotype-guided dosing. Primary endpoint data is anticipated to be completed by Q4 2027. Secondary outcomes include DPYD variant frequency, health economic and cost effectiveness analysis, and impact of dose adjustment on cancer outcomes. To date, 27 sites have been activated, with over 1200 participants enrolled. Completion of this study will inform a standardised approach for DPYD genotyping to minimise FP complications in Australia. Clinical trial information: ACTRN12623001301651 .
Jm et al. (Sat,) studied this question.